Cyclic Nucleotide Phosphodiesterases, Type 5
"Cyclic Nucleotide Phosphodiesterases, Type 5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.
| Descriptor ID |
D054706
|
| MeSH Number(s) |
D08.811.277.352.640.150.500 D08.811.277.352.640.155.500 D12.644.360.008.500 D12.644.360.009.500 D12.776.476.008.500 D12.776.476.009.500
|
| Concept/Terms |
Cyclic Nucleotide Phosphodiesterases, Type 5- Cyclic Nucleotide Phosphodiesterases, Type 5
- Phosphodiesterase 5A, cGMP-Specific
- Phosphodiesterase 5A, cGMP Specific
- cGMP-Specific Phosphodiesterase 5A
- Phosphodiesterase 5A
- Phosphodiesterase Type 5
- Type 5, Phosphodiesterase
- Phosphodiesterase 5
- Phosphodiesterase-5
- Phosphodiesterase V
- cGMP-Binding, cGMP-Specific 3',5'-cyclic Nucleotide Phosphodiesterase
- PDE5 Phosphodiesterases
- Phosphodiesterases, PDE5
- Phosphodiesterase Type V
- Type V, Phosphodiesterase
|
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 5".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Hydrolases [D08.811.277]
- Esterases [D08.811.277.352]
- Phosphoric Diester Hydrolases [D08.811.277.352.640]
- 3',5'-Cyclic-AMP Phosphodiesterases [D08.811.277.352.640.150]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.150.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D08.811.277.352.640.155]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.155.500]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Intracellular Signaling Peptides and Proteins [D12.644.360]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.644.360.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.644.360.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.009.500]
- Proteins [D12.776]
- Intracellular Signaling Peptides and Proteins [D12.776.476]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.776.476.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.776.476.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.009.500]
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 5".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in this website by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 2 | 3 |
| 2010 | 1 | 0 | 1 |
| 2019 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in Profiles.
-
Wang G, Shen D, Zhang X, Ferrini MG, Li Y, Liao H. Comparison of critical biomarkers in 2 erectile dysfunction models based on GEO and NOS-cGMP-PDE5 pathway. Medicine (Baltimore). 2021 Oct 15; 100(41):e27508.
-
Ferrini MG, Abraham A, Nguyen S, Luna R, Flores M, Artaza JN, Graciano L, Rajfer J. Exogenous l-ARGININE does not stimulate production OF NO or cGMP within the rat corporal smooth muscle cells in culture. Nitric Oxide. 2019 08 01; 89:64-70.
-
Ojo OA, Afon AA, Ojo AB, Ajiboye BO, Okesola MA, Aruleba RT, Adekiya TA, Oyinloye BE. Spondias mombim L. (Anacardiaceae): Chemical fingerprints, inhibitory activities, and molecular docking on key enzymes relevant to erectile dysfunction and Alzheimer's diseases. J Food Biochem. 2019 03; 43(3):e12772.
-
Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One. 2011 Apr 28; 6(4):e19329.
-
Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010 Apr; 7(4):215-21.
-
Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. Int J Impot Res. 2008 Jan-Feb; 20(1):30-4.
-
Devan BD, Pistell PJ, Daffin LW, Nelson CM, Duffy KB, Bowker JL, Bharati IS, Sierra-Mercado D, Spangler EL, Ingram DK. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester. Eur J Pharmacol. 2007 Jun 01; 563(1-3):134-40.
-
Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod. 2007 May; 76(5):915-23.